Last month, SII and Novavax submitted modules required by regulatory agencies in India, Indonesia and the Philippines to initiate a review of the vaccine. Credit: Klaus Hausmann / Pixabay.

and its partner Serum Institute of India (SII) have submitted an application to the World Health Organization (WHO) seeking emergency use listing (EUL) for the former鈥檚 Covid-19 vaccine candidate, NVX-CoV2373.

A recombinant nanoparticle protein-based vaccine candidate, NVX-CoV2373 is created from the genetic sequence of the first strain of the SARS-CoV-2 virus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile 鈥� free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

It is formulated with to boost the immune response and induce increased levels of neutralising antibodies.

The submission to WHO is based on Novavax and SII鈥檚 prior regulatory submission to the Drugs Controller General of India (DCGI).

The WHO EUL is necessary to export to several countries that are part of the COVAX Facility, which was set up to allot and supply vaccines equitably to participating countries and economies.

Last month, the companies concluded the submission of modules needed by regulatory authorities in India, Indonesia and the Philippines to commence the review of the vaccine, including preclinical, clinical and chemistry, manufacturing and controls (CMC) data.

Novavax president and CEO Stanley Erck said: 鈥淭oday鈥檚 submission of our protein-based Covid-19 vaccine to WHO for emergency use listing is a significant step on the path to accelerating access and more equitable distribution to countries in great need around the world.

鈥淚t represents another major milestone in Novavax鈥檚 transformation into a commercial global vaccine company and reinforces the value of global collaboration and need for multiple approaches to help control the pandemic.鈥�

Earlier this month, the Government of Japan鈥檚 Ministry of Health, Labour and Welfare agreed to聽procure 150 million doses of Novavax鈥檚 Covid-19 vaccine candidate聽produced by in the country on obtaining approval.

Separately, Novavax has reported full data from a pivotal Phase III clinical trial of its recombinant quadrivalent seasonal influenza vaccine candidate with Matrix-M adjuvant NanoFlu.

Results showed that NanoFlu was well-tolerated and induced substantially higher humoral and cellular immune responses as against the comparator vaccine.

NanoFlu has already met the primary goal of the trial, showing non-inferior immunogenicity to Fluzone Quadrivalent against all four influenza virus strains included in the vaccine.